E!10082, rosaGBS, ProNoxis
| Reference number | |
| Coordinator | PRONOXIS AB |
| Funding from Vinnova | SEK 3 732 312 |
| Project duration | April 2016 - March 2019 |
| Status | Completed |
| Venture | Eurostars |
Important results from the project
The conclusive results show that ProNoxis’ compounds are superior regarding potency and selectivity for the FPR/NOX2 target. The compounds have been confirmed by Neurix to be non- neurotoxic and by RedGlead to have good bioavailability properties. The compounds have effect in inflammation as well as autoimmunity and cancer.
Expected long term effects
We have in this project developed, as far as we know, some of the world’s most selective and potent FPR1/NOX2 agonist. We will develop these further and in collaboration with academic and industrial partners further develop and are based on the results from this project able to use these compounds for characterisation in immune system and diseases where specific FPR1/NOX2 activation may play a beneficial role.
Approach and implementation
We have during the duration of the project held more that 25 steering group meetings. In addition to the above meetings between all partners, we have held shorter project and study updates via Skype, telephone and mail to facilitate method development, technical questions and data analyses directly related to tasks and work packages, respectively. We have in the project established a secure platform data sharing and storage server for sharing documents between rosaGBS partners.